Botulinum Toxin Injections for Neurogenic Detrusor Overactivity Questions & Answers

1. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005 Sep. 174(3):977-82; discussion 982-3. [Medline].

2. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology. 2005 Jul. 66(1):94-8. [Medline].

3. Tullman M, Chartier-Kastler E, Kohan A, Keppenne V, Brucker BM, Egerdie B, et al. Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS. Neurology. 2018 Aug 14. 91 (7):e657-e665. [Medline].

4. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005 Jul. 174(1):196-200. [Medline].

5. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004 Jul. 172(1):240-3. [Medline].

6. Kim SW, Choi JH, Lee YS, Han SW, Im YJ. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity. Urology. 2014 Dec. 84 (6):1480-4. [Medline].

7. Peyronnet B, Castel-Lacanal E, Manunta A, Roumiguié M, Marque P, Rischmann P, et al. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin. Int J Urol. 2015 Sep 22. [Medline].

8. Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011 Apr. 185(4):1344-9. [Medline].

9. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol. 2006 Mar. 49(3):528-35. [Medline].

Pamela I Ellsworth, MD Chief, Division of Pediatric Urology, Nemours Children's Hospital; Professor of Urology, University of Central Florida College of Medicine

Pamela I Ellsworth, MD is a member of the following medical societies: American Urological Association, Massachusetts Medical Society, Society for Fetal Urology, Society of Women in Urology

Disclosure: Nothing to disclose.

Edward David Kim, MD, FACS Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American Society for Reproductive Medicine, American Urological Association, Sexual Medicine Society of North America, Tennessee Medical Association, Society for Male Reproduction and Urology, Society for the Study of Male Reproduction

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Endo.

• Print this section
• Print the entire contents of
• Print the entire contents of article